Back to Journals » Drug, Healthcare and Patient Safety » Volume 13

Potential Benefits of the Self-Administration of Subcutaneous Methotrexate with Autoinjector Devices for Patients: A Review

Authors Tornero Molina J, López Robledillo JC, Casamira Ruiz N

Received 7 November 2020

Accepted for publication 2 March 2021

Published 29 March 2021 Volume 2021:13 Pages 81—94

DOI https://doi.org/10.2147/DHPS.S290771

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Dr Hemalkumar B Mehta


Jesús Tornero Molina,1 Juan Carlos López Robledillo,2 Núria Casamira Ruiz3

1Department of Rheumatology, Hospital de Guadalajara, Guadalajara, Spain; 2Department of Rheumatology, Hospital del Niño Jesús, Madrid, Spain; 3Medical Department, Gebro Pharma S.A, Barcelona, Spain

Correspondence: Núria Casamira Ruiz
Medical Department, Gebro Pharma S.A, Avenida del Tibidabo, 29, Barcelona, 08022, Spain
Tel +34932058686
Fax +34932058684
Email [email protected]

Abstract: The role of patient adherence in improving the efficacy of any treatment is widely accepted, as well as its impact in optimizing the use of healthcare resources and associated costs. Adherence is particularly affected in chronic conditions, such as rheumatoid arthritis (RA), requiring long-term therapies and a commitment of the patient to manage his/her disease. Methotrexate (MTX) is one of the mainstays of treatment for several immune-mediated inflammatory joint and skin diseases, especially RA. The use of parenteral MTX, particularly when administered as a subcutaneous (SC) injection, has recently raised a great interest to overcome the limitations of oral MTX. For addressing this issue, new optimized self-injection systems have been developed to improve the ease of use of SC MTX. Increasing evidence shows how patients tend to opt for autoinjectors over prefilled syringes or conventional syringes in terms of easiness of use, preference and satisfaction, regardless of whether the treatment is a biologic or MTX. Additionally, positive views and beliefs of patients about treatment may contribute to increasing expectations of effectiveness and treatment adherence. Similarly, the implementation of prefilled pens in clinical practice might be a way to facilitate and simplify the self-injection of SC MTX delivery, optimizing adherence and treatment outcomes as a consequence. This article aimed to review the available literature data on the use of MTX autoinjectors and their impact on treatment adherence and patients’ perceptions.

Keywords: adherence, rheumatoid arthritis, methotrexate, autoinjector

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]